Injective (INJ) is currently priced at $2.81, reflecting a 24-hour change of -2.78%. The daily range has been tight, oscillating between a low of $2.79 and a high of $2.91, indicating a lack of volatility in the short term.

Trading volume over the past 24 hours is approximately 33.3 million, which equates to a volume-to-market cap ratio of 11.85%. This relatively low volume suggests a cautious market sentiment, as investors may be hesitant to take positions amid recent price declines.

The short-term moving averages reflect bearish momentum, with the 8 SMA at $2.85 showing a decline of 1.53% and the 13 SMA at $2.87 down 1.95%. The 21 and 55 SMAs further confirm this trend, with declines of 2.18% and 4.15% respectively, indicating persistent selling pressure.

The Relative Strength Index (RSI) readings corroborate the bearish outlook, with the 1-hour RSI at 30, indicating oversold conditions. Meanwhile, the 7-day RSI at 45 shows that the asset is nearing neutral territory but still reflects weakness, particularly in light of a 10.73% price drop over the past week.

Fundamentally, the price is significantly lower than its all-time high of $52.62 reached in March 2024, indicating a strong downtrend since that peak. Additionally, the 14-day price change at -24% highlights significant losses over a two-week period, further emphasizing the challenges facing the asset.

In conclusion, given the current technical indicators, bearish moving averages, and weak RSI levels, the market sentiment for Injective (INJ) is currently negative. Therefore, the recommendation is to hold positions until there are signs of a reversal or stabilization in price momentum, as the prevailing trends do not support a bullish outlook at this time.